Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Inflectra (infliximab-dyyb) is administered via an intravenous (IV) infusion for the treatment of:
Fact Table | |
---|---|
Formula | C6428H9912N1694O1987S46 |
License | FDA approved |
Bioavailability | Not applicable (intravenous administration) |
Legal status | Prescription only |
Chemical Name | Infliximab |
Elimination half-life | Approximately 9.5 days |
Dosage (Strength) | 100 mg/vial |
Pregnancy | Consult a healthcare provider |
Brands | Inflectra, Remicade, Remsima |
Protein binding | Not extensively bound to plasma proteins |
PubChem CID | 16129606 |
MedlinePlus | a604000 |
ChEBI | 606143 |
ATC code | L04AB02 |
DrugBank | DB00065 |
KEGG | D02597 |
Routes of administration | Intravenous |
A treatment plan for you, including Inflectra dosing, will be decided by your healthcare provider. A healthcare professional will administer Inflectra IV infusion. Any questions or concerns may be referred to your healthcare provider.
Infliximab-dyyb is the active ingredient in Inflectra.
Dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose are the inactive ingredients.
Inflectra doses that are more than 5 mg per kg should not be administered to patients with moderate or severe heart failure.
Additionally, Inflectra should not be administered to patients with an allergy to any of its ingredients.
Inflectra side effects include but are not limited to infections, infusion-related reactions, headache, and abdominal pain are common Inflectra side effects. Tell your healthcare provider right away if you experience worrisome or persistent side effects.
Talk to your healthcare provider about Inflectra.
Inflectra. New York, NY: Pfizer Labs; 2023.